Johnson & Johnson
RANK
37
J&J is home to globally known household products such as Tylenol pain medication and Aveeno body lotion. But over the past year, its health care and pharmaceutical businesses made the most news. The company began distributing its Janssen single-dose COVID-19 vaccine in March 2021. Manufacturing problems and the vaccine’s lower efficacy compared with products from Pfizer-BioNTech and Moderna hindered its adoption, but as of May 2022 about 19 million doses had been administered in the U.S., and millions more internationally. In July 2021, J&J agreed to pay up to $5 billion as part of a nationwide settlement agreement to fund state and local efforts to address the opioid crisis. (The company admitted no wrongdoing related to marketing of its pain medications.) And in November 2021 the company announced that it would essentially become a pharma pure play; by late 2023, J&J will spin off its consumer products businesses as a separate company.
Nikos Pekiaridis—SOPA Images/LightRocket via Getty Images
Company Information
As of 2/1/2023
Country
U.S.
Headquarters
New Brunswick, N.J.
Industry
Pharmaceuticals
CEO
Joaquin Duato
Website
Company Type
Public
Ticker
JNJ
Revenues ($M)
$94,943
Profits ($M)
$17,941
Market Value ($M)
$441,168
Employees
141,700
Figures are for fiscal year ended Dec. 31, 2022. Market value as of Jan. 20, 2023. Sources: Bloomberg; S&P Global.
Key Financials (Last Fiscal Year)
$ millions
% change
Revenues ($M)
$93,775
13.6%
Profits ($M)
$20,878
41.9%
Assets ($M)
$182,018
-
Total Stockholder Equity ($M)
$74,023
-
Profit Ratios
Profit as % of Revenues
22.3%
Profits as % of Assets
11.5%
Profits as % of Stockholder Equity
28.2%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)
781
EPS % Change (from 2020)
41.7%
EPS % Change (5 year annual rate)
5.7%
EPS % Change (10 year annual rate)
8.4%
Total Return
Total Return to Investors (2021)
11.5%
Total Return to Investors (5 year, annualized)
11.1%
Total Return to Investors (10 year, annualized)
13.2%
Johnson & Johnson Rank History
Historical Data
| Year | Revenues ($M) | Profits ($M) | Assets ($M) | Total Stockholder Equity ($M) |
|---|---|---|---|---|
| 2021 | $82,5840.6% | $14,714-2.7% | $174,894 | $63,278 |
| 2020 | $82,0590.6% | $15,119-1.2% | $157,728 | $59,471 |
| 2019 | $81,5816.7% | $15,2971076.7% | $152,954 | $59,752 |
| 2018 | $76,4506.3% | $1,300-92.1% | $157,303 | $60,160 |
| 2017 | $71,8902.6% | $16,5407.3% | $141,208 | $70,418 |
SHOW MORE
Lists ranking Johnson & Johnson
Latest news for Johnson & Johnson
- Health
Johnson & Johnson is paying $17.3 billion to buy a company that helps your heart pump bloodNovember 1, 2022, 2:03 PM UTC - Conferences
Chief diversity officers on the key to leveling the corporate playing fieldSeptember 16, 2022, 7:00 PM UTC - Finance
The world’s 10 biggest pharmaceutical companies raked in over $700 billion in revenue in 2021August 15, 2022, 10:15 PM UTC - Health
Johnson & Johnson to stop selling talc-based baby powder as cancer lawsuits pile onAugust 11, 2022, 11:13 PM UTC
- The 2023 World's Most Admired Companies list;1:03Digital Features;
- Brainstorm Tech 2022: Digital Transformation For An Evolving Future;41:19Conferences, Brainstorm Tech;
- Most Powerful Women 2021 - Health Care In A Changed World;49:48Conferences, MPW Summit;
- Brainstorm Health 2022 - Building The Health Care Workforce of The Future;57:20Conferences, Brainstorm Health;
